Genome Biologics identifies novel tissue-specific RNAi therapies targeting the transcriptome of cardiovascular and cardiometabolic disease
Genome Biologics has raised $11.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2021.
Genome Biologics's investors include European Innovation Council, EISMEA.
Genome Biologics is headquartered in Hessen, Germany.
Genome Biologics identifies novel tissue-specific RNAi therapies targeting the transcriptome of cardiovascular and cardiometabolic disease
Genome Biologics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Genome Biologics — Funding & Investors." VCBacked, October 6, 2021, https://www.vcbacked.co/company/genome-biologics. Accessed July 20, 2026.
VCBacked. (2021). Genome Biologics — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/genome-biologics
{{cite web |title=Genome Biologics — Funding & Investors |url=https://www.vcbacked.co/company/genome-biologics |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated